Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

/PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Related Keywords

Norway ,Marco Renoldi ,Lars Nieba ,Maureen Deehan ,Malene Brondberg ,Frazer Hall David ,Pierre Dodion ,Erik Skullerud ,Jostein Dahle ,Leoi Gordon ,Head Of Corporate Development ,John Friend Professor Of Cancer Research ,Health Policy Partnership ,University Of Pennsylvania ,Northwestern University Feinberg School Of Medicine ,Nordic Nanovector ,John Friend Professor ,Cancer Research ,Northwestern University Feinberg School ,Biologics License Application ,Corporate Development ,David Dible ,Securities Trading ,